Home brain training program for adults after surgery for rare brain tumors
Tests home thinking-skills rehabilitation with RehaCom in people with rare brain tumors.
Key facts
- Who runs it
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 27 Jan 2025
- Expected to end
- Feb 2027
- Type of study
- Interventional
- Treatments tested
- RehaCom
- Record updated
- 19 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a rare brain tumor who are planned to have brain surgery (craniotomy). Participants do memory and thinking training at home with the RehaCom software.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Rare brain tumor (incidence <6 cases per 100,000 people/year), planned for craniotomy (surgery that opens the skull).
Main reasons for not taking part
- Having only a needle biopsy (stereotactic/frameless biopsy)
- Psychiatric disorders or taking psychotropic medications (drugs acting on mood or the mind)
- Known decline in memory or thinking not caused by the tumor
- Admitted on the same day as surgery, or severe impairment needing a rehabilitation centre
- Not a native Italian speaker, or no Windows PC or laptop with Internet
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults (age ≥18 years)
- Both sexes
- Patients with rare brain tumors (incidence <6 cases per 100,000 people/year)
- Candidates for craniotomy for rare brain tumors
- Native Italian speakers for cognitive and psychological evaluation and neuro-cognitive rehabilitation
Who cannot take part
- Patients admitted on the same day as the surgery
- Patients with psychiatric disorders or on psychotropic medications
- Patients undergoing stereotactic/frameless biopsy
- Patients with known cognitive decline (not due to the lesion)
- Patients with severe impairments referred to rehabilitation centers
- Patients without a Windows PC or laptop with Internet connection for neuro-cognitive rehabilitation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study focuses on rare brain tumors, which are heterogeneous entities with different morphological, biological, and clinical characteristics. Due to their rarity, many of these tumors fall under the RARECARE definition of rare tumors. The main objective of the study is to standardize care models and pathways for patients with rare brain tumors, using Artificial Intelligence (AI) and Machine Learning (ML) techniques to identify specific predictors of postoperative outcomes.
Read full original descriptionShow less
The study includes both retrospective and prospective phases, with the collection of clinical, cognitive, and psychological data at various time points. Patients will undergo an early neuro-cognitive rehabilitation program using the RehaCom software, which will be conducted at home. The goal is to improve the quality of life and care for patients through a multidisciplinary and innovative approach.
The group in the trial
- Single GroupTreatment being tested
This group includes all adult participants with rare brain tumors who will receive early neuro-cognitive rehabilitation using the RehaCom software.
Treatment: RehaCom
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- SIMPLIF-AI: SIMPLIFication and Standardization of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence
- Plain-language title
- Home brain training program for adults after surgery for rare brain tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 19 February 2026